STI-571: An anticancer protein-tyrosine kinase inhibitor

Biochemical and Biophysical Research Communications

Volumn 309, Issue 4, 2003, Pages 709-717

  Roskoski Jr , Robert ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABL; Actin; ATM; BCR; Bcr Abl kinase; c Abl; c Kit; c Src; Chronic myeloid leukemia; Cytosine arabinoside; DNA repair; Gleevec; Glivec; Imatinib; Interferon ; Leukemia; Myristic acid; Nuclear export sequence; Nuclear localization sequence; PD173955

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ABELSON MURINE LEUKEMIA ONCOVIRUS; ARTICLE; BIOAVAILABILITY; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GENE CLUSTER; GENE MUTATION; HUMAN; ONCOGENE; ONCOGENE BCR; ONCOGENE C ABL; PHILADELPHIA 1 CHROMOSOME; PREVALENCE; PRIORITY JOURNAL; PROTEIN DOMAIN;

MURINAE;

EID: 0141788346     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.08.055     Document Type: Review

References (46)

1. Cohen P. The origins of protein phosphorylation. Nat. Cell Biol. 4:2002;E127-E130.
2. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1:2002;309-315.
3. Hunter T., Sefton B.M. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl. Acad. Sci. USA. 77:1980;1311-1315.
4. Mouse Genome Sequencing Consortium, Initial analysis and comparative analysis of the mouse genome, Nature 420 (2002) 520-562.
5. Manning G G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 298:2002;1912-1934.
6. Blume-Jensen P., Hunter T. Oncogenic kinase signaling. Nature. 411:2001;355-365. A comprehensive review of protein-tyrosine kinases implicated in cancer.
7. Sawyers C.L. Chronic myeloid leukemia. New. Engl. J. Med. 340:1999;1330-1340.
8. The site for the American Cancer Society with links to cancer statistics for 2003 〈http://www.cancer.org〉.
9. Kurzrock R., Kantarjian H.M., Druker B.J., Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann. Int. Med. 138:2003;819-830. A comprehensive review of Bcr-Abl structure, biology, and therapy.
10. Nowell P.C., Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science. 132:1960;1497.
11. Rowley J.D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 243:1973;290-293.
12. Witte O.N., Dasgupta A., Baltimore D., Abelson D. Murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature. 283:1980;826-831.
13. de Klein A., van Kessel A.G., Grosveld G., Bartram C.R., Hagemeijer A., Bootsma D., Spurr N.K., Heisterkamp N., Groffen J., Stephenson J.R. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 300:1982;765-767.
14. Shtivelman E., Lifshitz B., Gale R.P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 315:1985;550-554.
15. Ben-Neriah Y., Daley G.Q., Mes-Masson A.M., Witte O.N., Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/ abl hybrid gene. Science. 233:1986;212-214.
16. Heisterkamp N., Groffen J. Philadelphia-positive leukemia: a personal perspective. Oncogene. 21:2002;8536-8540.
17. Konopka J.B., Watanabe S.M., Witte O.N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 37:1984;1035-1042.
18. Ramakrishnan L., Rosenberg N. abl genes. Biochim. Biophys. Acta. 989:1989;209-2254. An authoritative review of the characterization of Abl protein-tyrosine kinase activity and chronic myeloid leukemia.
19. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science. 247:1990;824-830.
20. Kelliher M.A., McLaughlin J., Witte O.N., Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA. 87:1990;6649-6653.
21. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
22. Druker B.J., Lydon N.B. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105:2000;3-7.
23. Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1:2002;493-502.
24. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:1996;561-566. The first report on the efficacy of STI-571 in a pre-clinical setting.
25. Knighton D.R., Zheng J.H., Ten Eyck L.F., Ashford V.A., Xuong N.H., Taylor S.S., Sowadski J.M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 253:1991;407-414. The first description of the tertiary structure of a protein kinase that serves as a model for all protein kinases.
26. Hanks S.K., Quinn A.M., Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 241:1988;42-52.
27. Taylor S.S., Radzio-Andzelm E., Hunter T. How do protein kinases discriminate between serine/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase. FASEB J. 9:1995;1255-1266.
28. Konopka J.B., Witte O.N. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol. Cell Biol. 5:1985;3116-3123.
29. Koradi R., Billeter M., Wüthrich K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graphics. 14:1996;51-55.
30. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942. The first description of the binding of a congener of STI-571 to c-Abl.
31. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., Clarkson B., Superti-Furga G., Kuriyan J. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 112:2003;859-871. Description of the intramolecular regulation of c-Abl protein kinase and a comparison with that of c-Src protein kinase.
32. Johnson L.N., Noble M.E.M., Owen D.J. Active and inactive protein kinases: structural basis for regulation. Cell. 85:1996;149-158.
33. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell. 109:2002;275-282.
34. ′ -monophosphate dependent protein kinase: a new fluorescence displacement titration technique for mapping the nucleotide-binding site on the catalytic subunit Biochemistry. 22:1983;6310-6317.
35. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62:2002;4236-4243.
36. Harrison S.C. Variation on an Src-like theme. Cell. 112:2003;737-740.
37. Brasher B.B., Van Etten R.A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 275:2000;35631-35637.
38. Pendergast A.M. The Abl family kinases: mechanisms of regulation and signaling. Adv. Cancer Res. 85:2002;51-100.
39. Tauchi T., Miyazawa K., Feng G.S., Broxmeyer H.E., Toyama K. A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules. J. Biol. Chem. 272:1997;1389-1394.
40. Hubbard S.R., Till J.H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69:2000;373-398.
41. Smith K.M., Van Etten R.A. Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization. J. Biol. Chem. 276:2001;24372-24379.
42. S.W. Cowan-Jacob, V. Guez, G. Fendrich, D. Fabbro, P. Furet, J. Liebetanz, J. Mestan, P.W. Manley, Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment, Mini Rev. Med. Chem. (2003) in press.
43. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1031-1037. The first full paper describing the effect of STI-571 on the stable phase of chronic myeloid leukemia.
44. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:2001;1038-1042.
45. Corbin A.S., Rosee P.L., Stoffregen E.P., Druker B.J., Deininger M.W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 101:2003;4611-4614.
46. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D., Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:2002;472-480.